
Stanford Health Care’s Janjri Desai, Pharm.D., says pharmacists improve outcomes but often can’t bill for it, making billing parity key to growing services.
While plan managers have been doing it for nearly two decades with oral medications that are paid on the pharmacy benefit, the product-preferencing process is relatively novel for injectable medications. The next natural discussion is the role of benefit designs in the management of the cost of injectable products, since this is closely tied to product preferencing.